Tariffs and cross-border costs challenge life sciences M&A

Speaking with Lexpert for a recent feature on trends in health and life sciences M&A, Marcus Hinkley, partner and member of Gowling WLG’s global Life Sciences Group, offered insight into the pricing and policy concerns facing Canadian companies selling into U.S. markets.

As geopolitical uncertainty and inflationary pressure continue to weigh on deal activity in the sector, Marcus pointed to tariffs as a key factor shaping decisions on both sides of the border.

“[I]f it costs $10,000 to manufacture a medical device in Canada, which you then sell into the U.S. where it is subject to tariffs, you’re either going to have to take a loss on the product, or you’re potentially going to lose a sale because it’s more expensive,” he said.

To read the full article, click the link below (subscription may be required):

• Health and life sciences M&A in the waiting room as tariff and economic uncertainty grow

About Gowling WLG's Life Sciences Group

From intellectual property protection and regulatory approval to product liability and distribution, Gowling WLG's Life Sciences Group helps businesses and innovators navigate the complexities of the health and life sciences sector. With extensive experience across key global markets, our team delivers practical, business-focused advice at every stage of the product life cycle. Learn more.